Arca
Skip to content
Tools
Tools

CD22: B-cell receptor CD22

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow.

  • Drugs that act on it: 13
  • Approved: 2
  • In phases 1 to 3: 10
  • Sponsors: 7

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CD22, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody
  • Antibody-drug conjugate
  • Other

Approved2

  • Inotuzumab ozogamicin
  • Moxetumomab pasudotox

Phase 34

  • Inotuzumab
  • Epratuzumab
  • Bectumomab
  • Epratuzumab 90Y

Phase 23

  • BL22
  • Pinatuzumab vedotin
  • Yttrium y 90 epratuzumab tetraxetan

Phase 13

  • Epratuzumab-cys-tesirine
  • MONO-DGA-RFB4
  • Yttrium y 90 epratuzumab

Preclinical or unknown1

  • IMMURAIT-LL2

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • MedImmune LLC18%
  • UCB Pharma18%

Modalities

Drugs on this target by ChEMBL molecule type.

  • Antibody646%
  • Antibody-drug conjugate431%
  • Other323%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 9 of 13 act as: CD22 binding agent; the rest name their own mechanism.
Inotuzumab ozogamicinApprovedPfizerAntibody-drug conjugateBinding agent—38Boxed warning
Moxetumomab pasudotoxApprovedInnate PharmaAntibody-drug conjugateBinding agent—1Boxed warning
InotuzumabPhase 3BeOne MedicinesAntibodyBinding agent—38—
EpratuzumabPhase 3UCB PharmaAntibodyInhibitorCD22 inhibitor1—
BectumomabPhase 3—AntibodyOtherCD22 other0—
Epratuzumab 90YPhase 3Gilead SciencesAntibodyBinding agent—0—
BL22Phase 2MedImmune LLCOtherBinding agent—0—
Pinatuzumab vedotinPhase 2RocheAntibody-drug conjugateBinding agent—0—
Yttrium y 90 epratuzumab tetraxetanPhase 2Gilead SciencesAntibodyInhibitorCD22 inhibitor0—
Epratuzumab-cys-tesirinePhase 1—Antibody-drug conjugateBinding agentB-cell receptor CD22 binding agent0—
MONO-DGA-RFB4Phase 1—OtherBinding agent—0—
Yttrium y 90 epratuzumabPhase 1—AntibodyBinding agent—0—
IMMURAIT-LL2Preclinical or unknown—OtherBinding agent—0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.
Inotuzumab Plus Venetoclax in Older or Unfit Patients With Newly Diagnosed BCR::ABL1-Negative B-ALLInotuzumab ozogamicin, InotuzumabPhase 2Not yet recruitingRuijin Hospital2026-11-17
Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)Inotuzumab ozogamicin, InotuzumabPhase 1RecruitingSunil G. Iyer2026-11-13
Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALLInotuzumab ozogamicin, InotuzumabNot applicableNot yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2026-11-06
Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic LeukemiaInotuzumab ozogamicin, InotuzumabPhase 2Not yet recruitingPETHEMA Foundation2026-10-07
Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLInotuzumab ozogamicin, InotuzumabPhase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2026-09-25
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaInotuzumab ozogamicin, InotuzumabPhase 1 / Phase 2Not yet recruitingBeOne Medicines2026-08-18
Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella TrialInotuzumab ozogamicin, InotuzumabPhase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2026-06-11
Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic LeukemiaInotuzumab ozogamicin, InotuzumabNot applicableRecruitingInstitute of Hematology & Blood Diseases Hospital, China2026-03-27
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)EpratuzumabPhase 3RecruitingCharite University, Berlin, Germany2026-03-17
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell LeukemiaMoxetumomab pasudotoxPhase 1Active, not recruitingNational Cancer Institute (NCI)2019-01-16

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Neoplasm
0.49
Precursor B-cell acute lymphoblastic leukemia
0.30
Sjogren syndrome
0.26
Mixed phenotype acute leukemia
0.26

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3218, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P20273, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.